Abstracts Archive - Page 2014 of 2607 - ACR Meeting Abstracts

Abstract Number: 2149 • 2015 ACR/ARHP Annual Meeting
Dose Reduction Compared with Standard Dosing for Maintenance of Remission in Patients with Spondyloarthropathies and Clinical Remission with Anti-TNF: A Randomised Real-Life Trial
Jorge Gratacos-Masmitja¹, Caridad Pontes², Ferran Torres³, Xavier Juanola⁴, Antoni Vallano⁵, TC Salman-Monte⁶, Francisco J. Blanco⁷, Agusti Sellas-Fernandez⁸, Raimon Sanmarti⁹, Gonzalo Calvo¹⁰, Teresa Clavaguera¹¹, Raul Veroz Gonzalez¹², Juan Carlos Torre Alonso¹³, Jesus Sanz¹⁴, Cristina Avendaño¹⁵, Carlos Rodriguez-Lozano¹⁶, Luis Francisco Linares¹⁷, Ana Urruticoechea¹⁸, Eduardo Collantes-Estévez¹⁹, Rosa Morla Novell²⁰, Delia Reina²¹, Eduardo Cuende²², Pedro Zarco²³, Cruz Fernández- Espartero²⁴, Rosario Garcia-Vicuña²⁵, Carlos Alberto Montilla Morales²⁶, Eugenio De Miguel²⁷, Roser Vives² and Mireia Moreno²⁸, ¹Rheumatology, Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, ²Clinical Pharmacology, Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, ³Biostatistics and Data Management Platform, IDIBAPS - Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ⁵Hospital de Bellvitge, Barcelona, Spain, ⁶Rheumatology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, ⁷Osteoarticular and Aging Research Lab. Proteomics Unit - Associated Node to ProteoRed, Rheumatology Division, Proteomics Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ⁸Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, ⁹Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ¹⁰Hospital Clínic de Barcelona, Barcelona, Spain, ¹¹CapiCAT group (Nailfold Capillaroscopy group from the Catalan Society for Rheumatology)., Catalonia, Spain, ¹²Hospital de Mérida, Mérida, Spain, ¹³Perez de la Sala 33, 3oA., H. Monte Naranco, Oviedo, Spain, ¹⁴Rheumatology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁵Hospital Puerta de Hierro - Majadahonda, Madrid, Spain, ¹⁶Hospital Ubniversitario Dr. Negrin, Las Palmas de Gran Canaria, Spain, ¹⁷Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ¹⁸Hospital Can Misses, Ibiza, Spain, ¹⁹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²⁰Rheumatology UNit., Hospital Sta Tecla, Tarragona, Spain, ²¹Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ²²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ²³H Fundación Alcorcón, Alcorcón, Spain, ²⁴Rheumatology, Hospital La Zarzuela, Madrid, Spain, ²⁵Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁶Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ²⁷Rheumatology, University Hospital La Paz, Madrid, Spain, ²⁸Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain
Background/Purpose: Tumour Necrosis Factor alpha inhibitors (TNFi) have proven to be effective in the treatment of with spondyloarthropaties. There is rationale to support that in…
Abstract Number: 2150 • 2015 ACR/ARHP Annual Meeting
Treatment with Abatacept Prevents Experimental Dermal Fibrosis and Induces Regression of Established Inflammation-Driven Fibrosis
Matthieu Ponsoye¹, Camelia Frantz², Nadira Ruzehaji³, Muriel Elhai⁴, Barbara Ruiz¹, Anne Cauvet¹, Yannick Allanore⁵ and Jerome Avouac⁴, ¹INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ³INSERM U1016, Paris Descartes University, Paris, France, ⁴Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ⁵Paris Descartes University, Rheumatology A department, Cochin Hospital, And Eular Scleroderma Trials And Research (EUSTAR) Board, Paris, France
Background/Purpose: Early stages of systemic sclerosis (SSc) are characterized by inflammatory skin infiltrates mainly composed of activated T cells. Cytotoxic T-lymphocyte associated molecule-4 (CTLA-4) is…
Abstract Number: 2151 • 2015 ACR/ARHP Annual Meeting
Inhibition of Myeloid-Associated Gene Expression in Skin Biopsy Samples of Systemic Sclerosis Patients Treated with Tocilizumab
Thierry Sornasse¹, Haiyin Chen¹, Lisa Rice², Giuseppina Stifano², Angelika Jahreis¹, Jeffrey Siegel¹ and Robert Lafyatis², ¹Genentech, South San Francisco, CA, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a progressive, debilitating disease with limited treatment options. IL-6 has been implicated in disease pathogenesis. Tocilizumab (TCZ), an IL-6Rα inhibitor,…
Abstract Number: 2152 • 2015 ACR/ARHP Annual Meeting
Long Noncoding H19X Is a Key Mediator of Tgf-Beta Induced Pro-Fibrotic Effects in the Pathogenesis of Systemic Sclerosis and Other Fibrotic Diseases
Elena Pachera¹, Shervin Assassi², Gloria Salazar², Mojca Frank Bertoncelj³, Rucsandra Dobrota⁴, Matthias Brock⁵, Serena Vettori⁶, Claus Hellerbrand⁷, Carol A. Feghali-Bostwick⁸, Jeorg HW Distler⁹, Gabriela Kania¹⁰ and Oliver Distler¹¹, ¹Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, Schileren, Switzerland, ²Rheumatology, University of Texas Medical School at Houston, Houston, TX, ³Center of Experimental Rheumatology, University Hospital Zurich, University Zurich, Zurich, Switzerland, ⁴Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Department of Pulmonology, University Hospital Zurich, Schileren, Switzerland, ⁶Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁷Department of Internal Medicine I, University of Regensburg, Regensburg, Germany, ⁸Medicine, University of Pittsburgh, Pittsburgh, PA, ⁹Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, 8952 Schlieren, Switzerland, ¹¹Division of Rheumatology, University Hospital And Eular Scleroderma Trials And Research (EUSTAR) Board, Zurich, Switzerland
Background/Purpose: Long noncoding RNAs (LncRNAs) are emerging as a novel class of noncoding transcripts involved in the regulation of gene expression. So far, for only…
Abstract Number: 2153 • 2015 ACR/ARHP Annual Meeting
Nintedanib Ameliorates Fibrotic and Vascular Manifestations in Preclinical Models of Systemic Sclerosis
Jingang Huang¹, Christian Beyer¹, Yun Zhang¹, Katrin Palumbo-Zerr², Clara Dees¹, Oliver Distler³, Georg A. Schett⁴, Stefan Lutz Wollin⁵ and Jorg HW. Distler¹, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Rheumatology, Research of Systemic Autoimmune Diseases, University Hospital Zurich, Zurich, Switzerland, ⁴Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Boehringer-Ingelheim Pharma, Div. Research Germany, Bad Biberach, Germany
Background/Purpose: Nintedanib is a tyrosine kinase inhibitor that inhibits PDGF-, FGFR-, VEGFR-receptors and Src kinases. Nintedanib has recently been approved for the treatment of idiopathic…
Abstract Number: 2154 • 2015 ACR/ARHP Annual Meeting
Inhibition of Gli Ameliorates the Pro-Fibrotic Effects of Transforming Growth Factor-Î² in Systemic Sclerosis
Ruifang Liang¹, Clara Dees², Katrin Palumbo-Zerr³, Yun Zhang³, Oliver Distler⁴, Georg Schett³ and Jeorg HW Distler³, ¹Rheumatology and Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Division of Rheumatology, University Hospital And Eular Scleroderma Trials And Research (EUSTAR) Board, Zurich, Switzerland
Background/Purpose: Hedgehog signaling plays a critical role in the pathogenesis of fibrosis in Systemic sclerosis (SSc). Besides canonical hedgehog signaling with Smoothened (Smo)-dependent activation of…
Abstract Number: 2155 • 2015 ACR/ARHP Annual Meeting
Inhibition of Sphingosine-1-Phosphate Signaling By AB22 As a Novel Strategy in the Treatment of Pulmonary Fibrosis Associated with Scleroderma
Ilia Atanelishvili¹, Yuichiro Shirai², Tanjina Akter³, Erik Stolarzewicz⁴, Rolf E Swenson⁵, Richard Silver⁶ and Galina S. Bogatkevich⁷, ¹Division of Rheumatology & Immunology, Medical University of South Carolina,Charleston,USA, Charleston, SC, ²Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ³Medical University of South Carolina, charleston, SC, ⁴Chem-Master International Inc, Stony Brook, NY, ⁵Arroyo BioSciences, Silver Spring, MD, ⁶Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ⁷Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Activation of sphingosine-1-phosphate (S1P) signaling has been extensively documented in various fibrotic conditions including pulmonary fibrosis. The aim of this study was to provide…
Abstract Number: 2156 • 2015 ACR/ARHP Annual Meeting
Damage Assessment in Giant Cell Arteritis
Tanaz A. Kermani¹, Antoine G. Sreih², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁵, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux⁴, Philip Seo¹¹, Kenneth J. Warrington¹², Steven R. Ytterberg¹² and Peter A. Merkel¹³, ¹Rheumatology, University of California Los Angeles, Santa Monica, CA, ²Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Rheumatology, Mayo Clinic, Rochester, MN, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: This study aimed to 1) catalogue damage in a longitudinal cohort of patients with giant cell arteritis (GCA) and 2) evaluate predictors of…
Abstract Number: 2157 • 2015 ACR/ARHP Annual Meeting
Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis
Matthew J. Koster¹, Cristian Labarca², Cynthia S. Crowson³, Ashima Makol¹, Steven R. Ytterberg⁴, Eric L. Matteson¹ and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Relapses in patients with giant cell arteritis (GCA) are common and often lead to higher cumulative use of glucocorticoids. This study aims to evaluate…
Abstract Number: 2158 • 2015 ACR/ARHP Annual Meeting
Mortality Associated with Giant Cell Arteritis from 1980 to 2011: An Analysis of the French National Death Certificate Database
Achille Aouba¹, Solange Gonzalez-Chiappe², Mireille Eb³, Claire Delmas¹, Grégoire Rey³, Alfred Mahr² and Boris Bienvenu¹, ¹Internal Medicine, Hospital Caen, Caen, France, ²Internal Medicine, Hospital Saint-Louis, Paris, France, ³Inserm-CépiDc, Hospital Bicêtre, Le Kremlin-Bicêtre, France
Background/Purpose: Data from mostly small cohorts consistently suggest that a diagnosis of giant cell arteritis (GCA) does not substantially affect survival but GCA- and GCA…
Abstract Number: 2159 • 2015 ACR/ARHP Annual Meeting
Second Temporal Artery Biopsies in Patients with Temporal Arteritis (TA)
John Fritzlen¹, Brian Younge², Cornelia M. Weyand³, Gene G. Hunder⁴, Jorg Goronzy⁵, Kenneth J. Warrington⁴ and Joseph Maleszewski¹, ¹Anatomical Pathology, Mayo Clinic, Rochester, MN, ²Ophthalmology, Mayo Clinic, Rochester, MN, ³Stanford, Stanford, CA, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Emory University School of Medicine, Lowance Center for Human Immunology and Rheumatology, Atlanta, GA
Background/Purpose: While many manifestations of TA improve quickly after starting glucocorticoid therapy, vascular inflammation appears to persist. To obtain more information about the duration of…
Abstract Number: 2160 • 2015 ACR/ARHP Annual Meeting
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis: A Diagnostic Accuracy and Cost-Effectiveness Study
Raashid Luqmani¹, Ellen Lee², Surjeet Singh³, Michael Gillett², Wolfgang A. Schmidt⁴, Mike Bradburn², Bhaskar Dasgupta^5,6, Andreas P Diamantopoulos⁷, Wulf Forrester-Barker⁸, William Hamilton⁹, Shauna Masters¹⁰, Brendan McDonald¹¹, Eugene McNally⁸, Colin T. Pease¹², Jennifer Piper⁸, John Salmon¹³, Allan Wailoo², Konrad Wolfe¹⁴, Andrew Hutchings¹⁵ and TABUL Study group, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ³1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁵Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁶Southend University Hospital, Essex, United Kingdom, ⁷Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁹Primary Care, University of Exeter, Exeter, United Kingdom, ¹⁰Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ¹¹Department of Neuropathology and Ocular Pathology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹²Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹³Ophthalmology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹⁴Department of Pathology, Southend University Hospital, Essex, United Kingdom, ¹⁵Health Services Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculitis which if untreated can lead to permanent sight loss. It is…
Abstract Number: 2161 • 2015 ACR/ARHP Annual Meeting
Ustekinumab for the Treatment of Refractory Giant Cell Arteritis
Richard Conway^1,2, Lorraine O'Neill^3,4, Eileen O'Flynn³, Geraldine M. McCarthy^5,6, Conor Murphy⁷, Douglas J. Veale⁸, Ursula Fearon⁹ and Eamonn S. Molloy¹⁰, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁵Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁶University College Dublin, Dublin, Ireland, ⁷Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁸St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ⁹St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ¹⁰St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin 4, Dublin 4, Ireland
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high dose corticosteroids. Many patients require chronic steroid therapy with associated significant side effects. There is a…
Abstract Number: 2162 • 2015 ACR/ARHP Annual Meeting
Associations Between Education and Health Status Among Hispanics with Self-Reported Arthritis and/or Joint Pain
Leigha Vilen¹, Rebecca J. Cleveland², Alfredo Rivadeneira¹, Mary Altpeter³, Betsy Hackney⁴, Victoria Sepulveda² and Leigh F. Callahan⁴, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Institute on Aging, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC
Background/Purpose: Understanding the associations between education and health status among Hispanics with arthritis and/or joint pain is crucial in adapting existing arthritis interventions for this…
Abstract Number: 2163 • 2015 ACR/ARHP Annual Meeting
Associations Between Sex Differences, Pain, Insomnia, and Depression in Older Adults with Osteoarthritis: A Cross-Sectional Study
Minhui Liu¹, Susan McCurry¹, Michael Vitiello², Basia Belza¹ and Michael Von Korff³, ¹University of Washington School of Nursing, Seattle, WA, ²Psychiatry and Behavioral Sciences, Biobehavioral Nursing and Health Systems, University of Washington School of Medicine, Seattle, WA, ³Group Health Research Institute, Seattle, WA
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis and affects nearly 30 million Americans. Chronic pain is the major symptom in OA and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].